RHOPRESSA FDA Approval, LUMIFY Red Eye Relief, and MyDay Toric Release

RHOPRESSA FDA Approval, LUMIFY Red Eye Relief, & MyDay Toric Release

Welcome to what’s trending in eye care, brought to you by IntroWellness.com and OptomEyesLife! I’m Dr. Amanda Rights, here to bring you the news!

Introducing RHOPRESSA, the newest glaucoma therapy!

Last month, the FDA approved Aerie Pharmaceutical’s RHOPRESSA (netarsudil ophthalmic solution) 0.02%. This first-in-class therapy is for the treatment of patients with open-angle glaucoma and other diseases of the eye. It is expected to become available in the spring of 2018.

How does it work?

Rhopressa has a unique, triple-action mechanism of action. Through the inhibition of Rho Kinase (ROCK), it increases fluid outflow through the trabecular meshwork and lowers episcleral venous pressure. It also reduces fluid production in the eye by inhibiting the norepinephrine transporter (NET Inhibitor). While this is all fairly technical, it’s a fantastic new eye drop for your eye doctor to have in their glaucoma toolbox!

RHOPRESSA mechanism of action
Source: Rhopressa / Aerie Pharmaceuticals

What are the side effects?

Rhopressa has minimal systemic adverse effects and no contraindications. The biggest side effect was redness (conjunctival hyperemia) reported in 53% of patients.

How is it dosed?

Patients are to install one drop into their affected eye(s) once daily in the evening.

RELATED: Here’s What You Need To Know About Glaucoma Eye Drops

Say hello to brighter, whiter eyes with LUMIFY

The FDA has approved Bausch + Lomb’s LUMIFY (brimonidine tartrate ophthalmic solution 0.025%) as the first over-the-counter (OTC) eye drop developed with low-dose brimonidine tartrate for the treatment of ocular redness. it is expected to be available in the second quarter of 2018.

How does it work?

Red eyes are caused by swollen or dilated blood vessels on the white outer surface of the eye (conjunctiva). Brimonidine (the active ingredient in Lumify) selectively narrows blood vessels in the eye, which increases the availability of oxygen to the surrounding eye tissues so they appear brighter and whiter.

How is this different from Clear Eyes or VISINE?

Clear Eyes and VISINE are non-selective redness-relieving eye drops that constrict blood vessels in the eye. Frequent use of these eye medications may cause you to develop a tolerance or loss of effectiveness (known as tachyphylaxis), as well as rebound redness. In contrast, Lumify selectively constricts blood vessels in the eye, thereby reducing the likelihood of rebound redness.

LUMIFY is available in two sizes (0.08 ounce or 0.25 ounce) both of which you can purchase here!

MyDay toric release

CooperVision extended its MyDay product line with the release of MyDay Toric in the United States.

MyDay toric
Source: CooperVision

What is MyDay?

MyDay is a daily disposable contact lens that uses Smart Silicone technology to deliver oxygen to your eyes much more efficiently than other daily disposable brands while using less silicone. It also has both UVA and UVB protection.

RELATED: Toric Contact Lenses for Astigmatism: Are They Right for You?

January is Glaucoma Awareness Month

Glaucoma is a group of diseases that damage the eye’s optic nerve and can result in vision loss and blindness. At first, it has no symptoms. However, over time, glaucoma causes a slow loss of vision. It typically affects your peripheral (side) vision first and can progress until no vision remains.

January is Glaucoma Awareness Month
Source: OptomEyesLife⠀⠀⠀⠀⠀⠀⠀⠀

Whether you develop glaucoma depends on a number of factors, including the level of pressure (known as intraocular pressure) your optic nerve can tolerate without being damaged. This level is different for everyone and is why a comprehensive dilated eye exam is necessary to diagnose glaucoma and/or determine if you are at risk of developing it!

RELATED: Glaucoma: What Is It and Are You At Risk?

That’s all for what’s trending in eye care! Subscribe to our newsletter for more updates coming soon.

Facebook Comments